Avanos Medical (NYSE:AVNS) Updates FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.050-1.250 for the period, compared to the consensus earnings per share estimate of 1.670. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $713.1 million.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Price Performance

AVNS stock traded up $0.25 on Wednesday, reaching $15.81. 565,431 shares of the company’s stock were exchanged, compared to its average volume of 539,626. The firm has a market cap of $726.67 million, a PE ratio of 46.50 and a beta of 0.98. Avanos Medical has a twelve month low of $14.40 and a twelve month high of $25.36. The stock has a fifty day moving average of $16.15 and a 200-day moving average of $19.73. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. As a group, equities analysts predict that Avanos Medical will post 1.32 EPS for the current fiscal year.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.